ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Third Quarter results

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Nov 13, 2021 12:59pm

159 Views

Post# 34123327

RE:RE:RE:Third Quarter results

The Company is responsible to fund operating expenses, with prior notification of the planned expenditures, to bring the assay through regulatory approval.

This is the delay that is holding back everthing we expect to see or hear.

<< Previous

Bullboard Posts

Next >>

Get a better understanding of the psychology of options trading